A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

A Double-blind, Crossover, Placebo-Controlled, Multiple-dose Study to Evaluate the Effects of Vildagliptin on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes

This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.

Inclusion Criteria:

• Diagnosed with type 2 diabetes for at least 6 months
• Blood glucose criteria must be met
• BMI in the range 22-40

Exclusion Criteria:

• History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
• Use of thiazolidinediones or need for insulin within 3 months prior to screening
• Significant concomitant diseases or complications of diabetes
• High fasting triglycerides as defined by the protocol

Other protocol-defined inclusion/exclusion criteria may apply